Transient asymptomatic pulmonary opacities in a patient with MET exon 14 skipping non‐small cell lung cancer: A case report

Mesenchymal epithelial transition factor receptor (MET) tyrosine kinase inhibitors (MET‐TKIs) have been approved for the treatment of non‐small cell lung cancers with MET exon 14 skipping mutations. Transient asymptomatic pulmonary opacities (TAPOs) associated with epidermal growth factor receptor (...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeo, Satoshi, Yasuda, Naoaki, Sakai, Yuki, Hayashi, Yasuyuki, Sokai, Akihiko, Iwata, Toshiyuki, Nishimura, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067352/
https://www.ncbi.nlm.nih.gov/pubmed/36810936
http://dx.doi.org/10.1111/1759-7714.14831

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067352/
https://www.ncbi.nlm.nih.gov/pubmed/36810936
http://dx.doi.org/10.1111/1759-7714.14831

Ejemplares similares